P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer.
Livia Malorni(Beth Israel Deaconess Medical Center), Rachel Schiff(Baylor College of Medicine), HH He(Beth Israel Deaconess Medical Center), Carlos Gutiérrez(Beth Israel Deaconess Medical Center), C. Kent Osborne(Texas Oncology), Rinath Jeselsohn(Dana-Farber Cancer Institute), Nuala Healy(St. James's Hospital), Mario Giuliano(Regione Campania), Matthew Brown(Centre for Human Genetics), Abhijit Mazumdar(The University of Texas MD Anderson Cancer Center), Xaio-Dong Fu(Beth Israel Deaconess Medical Center), Ilenia Migliaccio(Hospital of Prato), MV Trivedi(Beth Israel Deaconess Medical Center), CJ Creighton(Beth Israel Deaconess Medical Center), SG Hilsenbeck(Beth Israel Deaconess Medical Center), Mathieu Lupien(Ontario Institute for Cancer Research), PH Brown(Beth Israel Deaconess Medical Center), T Wang(Beth Israel Deaconess Medical Center)
Cited by 1
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494